Name: Pioglitazone HCl
Price: 180.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Pioglitazone HCl is a potent and highly selective agonist of PPARγ with IC50 value of 3μM[1].Pioglitazone HCl can increase both insulin-stimulated glucose uptake in peripheral tissues and insulin sensitivity in hepatic and adipose tissue. It is treated for hyperglycemia and Type 2 diabetes (T2D). Pioglitazone needs insulin as a co-factor for PPAR agonism so it is not effect when being treated to late stages of T2D with developed insulinopenia. In clinical trials, 15mg pioglitazone produces significant improvements in HbA1c and fasting plasma glucose (FPG) [2].Pioglitazone is also reported to have multiple beneficial effects on lipid metabolism. It produces significant decreases in TG and significant increases in high density lipoprotein (HDL) in clinical studies [2].
    
    [1] Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant. 2009 Apr;24(4):1130-41.
    [2] Dorkhan M, Frid A. A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2007;3(5):721-31.
- Properties
  - Categories
    
    PPARγ agonist
    
    Alternative Name
    
    5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
    
    CAS Number
    
    112529-15-4
    
    Molecular Formula
    
    C19H20N2O3S·HCl
    
    Molecular Weight
    
    392.9
    
    Appearance
    
    A solid
    
    Purity
    
    98.39%
    
    Solubility
    
    insoluble in H2O; ≥19.65 mg/mL in DMSO; ≥7.52 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl
    
    * For Research Use Only